KIT and neoplasm: In contrast, 5 of the 6 mice injected with the 5 × 104 SKOV3 CD117+CD44+-shHOTAIR developed visible tumors on Day 14, Day 16, Day 18, Day 26, and Day 26, respectively, and the remaining 1 mouse did not develop tumor throughout the 64-day observation period.